Overview

Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)

Status:
Completed

Trial end date:
2007-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess whether a switch from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI- and/or health-related quality of life outcomes, and to determine the proportion of renal transplant recipients who are experiencing any GI complaints under MMF-based immunosuppressive treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Mycophenolate mofetil
Mycophenolic Acid